Mode
Text Size
Log in / Sign up
N/A N=55 Randomized Triple-blind Treatment

Analgesic Ointment on Temporomandibular Joint and Masticatory Muscle Pain

Temporomandibular Disorders

Enrolled (actual)
55
Serious AEs
0.0%
Results posted
Jun 2014
Primary outcome: Primary: The Efficacy in the Treatment of TMJ and Muscle Pain — 21.93; 40.81 units on a scale

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Ping On Ointment (Drug); Vaseline (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
The University of Hong Kong
Primary completion
Jun 2008

Outcome Measures

OutcomeResultp-value
PRIMARY
The Efficacy in the Treatment of TMJ and Muscle Pain
21.93; 40.81
SECONDARY
The Mandibular Function.
4.435; 0.818

Summary

The purpose of this study is to compare the effectiveness of using topical cream of Ping On Ointment and using Vaseline cream in the treatment of temporomandibular joint (TMJ) and masticatory muscle pain, in order to establish the true efficacy of Ping On Ointment. Both Ping On Ointment and Vaseline are considered intervention.

Eligibility Criteria

Inclusion Criteria

  • Self report of facial ache or pain in the muscles of mastication, the TMJ, or the region in front of ear or inside the ear
  • Positive clinical diagnosis of TMDs. The TMD diagnosis is classified using axis I of the research diagnostic criteria ( RDC) for TMDs. The RDC diagnosis consists of joint pain at rest ( spontaneous pain) and evoked pain (hyperalgesia) on palpation of the TMJ, TMJ reduction consists of reciprocal clicking or joint noise with mandibular movement examination.
  • For joint pain complaint, subjects will be required to have a self-report of at least 1 month of daily or nearly-daily pain.
  • Subjects with myogenic pain will be included if they meet inclusion and exclusion criteria since patients with TMDs are known to exhibit muscle pain secondary to their joint dysfunction.

Exclusion Criteria

  • Subjects with infectious arthritis, crystal induced arthropathies, musculoskeletal disorders, subjects with a primary diagnosis of myofascial pain based on the RDC;
  • Subjects with pain attributable to confirmed migraine or head pain condition other than tension headache;
  • Subjects with acute infection or other significant disease of teeth, ears, eyes, nose or throats; subjects with untreated depressive disorder or not on stable antidepressant medication for more than 6 months;
  • Subjects with dental diseases that required ongoing treatment, which would confound the evaluation of orofacial pain;
  • Subjects who are not competent in giving consents.
  • Pregnant or lactating women
  • Subjects with sensitivity to the ingredient of Ping On Ointment will be excluded.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00812604). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search